Published in Pediatr Crit Care Med on March 01, 2017
Thrombotic microangiopathy associated with Valproic acid toxicity. BMC Nephrol (2017) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 16.96
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 11.24
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 7.10
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature (2001) 6.95
A genomic storm in critically injured humans. J Exp Med (2011) 6.67
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med (2009) 4.98
Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet (2011) 4.70
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med (1991) 4.66
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol (2001) 4.49
Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet (2002) 4.42
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) Ann Intern Med (1996) 3.74
Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med (2005) 3.58
Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med (2011) 3.28
An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood (2004) 3.19
Essential roles of the Fas ligand in the development of hepatitis. Nat Med (1997) 3.05
An innate sense of danger. Semin Immunol (1998) 2.84
HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med (2001) 2.80
Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Med (2014) 2.70
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
Macrophage activation by endogenous danger signals. J Pathol (2008) 2.38
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood (2011) 2.35
Bench-to-bedside review: Cytopathic hypoxia. Crit Care (2002) 2.29
Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol (1999) 2.25
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A (2002) 2.23
Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2012) 2.22
Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med (2006) 2.21
Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol (2005) 2.17
Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med (2015) 2.09
Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Intensive Care Med (1996) 2.00
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med (2008) 1.97
Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest (1996) 1.96
Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med (2010) 1.95
Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.94
Advances in understanding the pathogenesis of HLH. Br J Haematol (2013) 1.92
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Admission angiopoietin levels in children with septic shock. Shock (2007) 1.82
Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med (2014) 1.80
Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med (2002) 1.80
Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med (2005) 1.79
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med (2016) 1.76
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest (2011) 1.75
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood (2010) 1.75
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem (2005) 1.74
Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol (2006) 1.73
Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med (2013) 1.71
Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med (2007) 1.68
Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med (2013) 1.64
Hemophagocytic syndromes--an update. Blood Rev (2014) 1.60
Mitochondrial dysfunction in peripheral blood mononuclear cells in pediatric septic shock. Pediatr Crit Care Med (2015) 1.59
Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med (2007) 1.58
Non-apoptotic Fas signaling. Cytokine Growth Factor Rev (2003) 1.57
Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion (2004) 1.56
Multiple, progressive, or sequential systems failure. A syndrome of the 1970s. Arch Surg (1975) 1.53
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol (2000) 1.47
Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med (1998) 1.43
Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci (2012) 1.42
Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med (2009) 1.39
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care (2013) 1.37
Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit Care Med (2006) 1.35
Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion (2012) 1.35
Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog (2009) 1.33
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant (2012) 1.29
Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood (2012) 1.25
Mitochondrial ROS production under cellular stress: comparison of different detection methods. Anal Bioanal Chem (2011) 1.24
The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest (1998) 1.24
Genetic influence on cytokine production in meningococcal disease. Lancet (1997) 1.23
Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med (1996) 1.17
Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med (2014) 1.16
von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood (2002) 1.16
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill. Crit Care (2006) 1.15
Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost (2009) 1.15
HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med (2008) 1.15
Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood (2013) 1.14
Mitochondria: isolation, structure and function. J Physiol (2011) 1.14
Mitochondrial dysfunction, bioenergetic impairment, and metabolic down-regulation in sepsis. Shock (2007) 1.12
Mitochondrial control of the NLRP3 inflammasome. Nat Immunol (2011) 1.12
Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? Crit Care Clin (2002) 1.12
Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood (2003) 1.10
Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med (2007) 1.10
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood (2003) 1.10
Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care (2012) 1.07
Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Crit Care (2011) 1.05
4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care (2010) 1.05
Mitochondria in lung biology and pathology: more than just a powerhouse. Am J Physiol Lung Cell Mol Physiol (2014) 1.04
Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol (2014) 1.04
Use of therapeutic plasma exchange in children with thrombocytopenia-associated multiple organ failure in the Turkish thrombocytopenia-associated multiple organ failure network. Pediatr Crit Care Med (2014) 1.03
Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev (2014) 1.03
High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res (2010) 1.02
Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med (2003) 1.02
Unexpected increased mortality after implementation of a commercially sold computerized physician order entry system. Pediatrics (2005) 15.40
Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics (2007) 3.37
Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med (2009) 3.16
Internalization and phagosome escape required for Francisella to induce human monocyte IL-1beta processing and release. Proc Natl Acad Sci U S A (2005) 2.82
Pediatric severe sepsis in U.S. children's hospitals. Pediatr Crit Care Med (2014) 2.43
Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med (2009) 2.23
Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2012) 2.22
Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med (2011) 2.20
Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol (2005) 2.17
Extracorporeal life support for severe respiratory failure in children with immune compromised conditions. Pediatr Crit Care Med (2008) 2.17
Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med (2015) 2.09
Leukocyte subset-derived genomewide expression profiles in pediatric septic shock. Pediatr Crit Care Med (2010) 2.01
The pediatric sepsis biomarker risk model. Crit Care (2012) 1.99
Fluid overload and fluid removal in pediatric patients on extracorporeal membrane oxygenation requiring continuous renal replacement therapy. Crit Care Med (2012) 1.99
In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood (2005) 1.99
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med (2008) 1.97
Validating the genomic signature of pediatric septic shock. Physiol Genomics (2008) 1.96
The ideal time interval for critical care severity-of-illness assessment. Pediatr Crit Care Med (2013) 1.91
Admission angiopoietin levels in children with septic shock. Shock (2007) 1.82
Weight-based determination of fluid overload status and mortality in pediatric intensive care unit patients requiring continuous renal replacement therapy. Intensive Care Med (2011) 1.79
Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency. Am J Pathol (2002) 1.78
Do outcomes vary according to the source of admission to the pediatric intensive care unit? Pediatr Crit Care Med (2008) 1.74
Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med (2013) 1.74
Pyrin critical to macrophage IL-1beta response to Francisella challenge. J Immunol (2009) 1.73
Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med (2006) 1.73
Post-ICU admission fluid balance and pediatric septic shock outcomes: a risk-stratified analysis. Crit Care Med (2014) 1.72
Comparison of SpO2 to PaO2 based markers of lung disease severity for children with acute lung injury. Crit Care Med (2012) 1.71
The role of different anesthetic techniques in altering the stress response during cardiac surgery in children: a prospective, double-blinded, and randomized study. Pediatr Crit Care Med (2013) 1.70
Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med (2003) 1.62
The host response to sepsis and developmental impact. Pediatrics (2010) 1.62
The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med (2011) 1.57
Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med (2014) 1.56
Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J Immunol (2006) 1.55
Failure to recover somatotropic axis function is associated with mortality from pediatric sepsis-induced multiple organ dysfunction syndrome. Pediatr Crit Care Med (2010) 1.55
IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol (2011) 1.55
Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med (2010) 1.51
Clinical course of sepsis in children with acute leukemia admitted to the pediatric intensive care unit. Pediatr Crit Care Med (2011) 1.51
Fatal and near-fatal asthma in children: the critical care perspective. J Pediatr (2012) 1.51
Multidisciplinary quality improvement initiative to reduce ventilator-associated tracheobronchitis in the PICU. Pediatr Crit Care Med (2013) 1.51
Clinical outcomes of children receiving intensive cardiopulmonary support during hematopoietic stem cell transplant. Pediatr Crit Care Med (2013) 1.50
Characteristics and outcomes of interhospital transfers from level II to level I pediatric intensive care units. Pediatr Crit Care Med (2006) 1.50
New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol (2010) 1.49
Feasibility and perceived benefits of a framework for physician-parent follow-up meetings after a child's death in the PICU. Crit Care Med (2014) 1.49
A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury. Crit Care Med (2015) 1.49
Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am (2008) 1.47
Going back for more: an evaluation of clinical outcomes and characteristics of readmissions to a pediatric intensive care unit. Pediatr Crit Care Med (2007) 1.44
Combined steroid treatment for congenital heart surgery improves oxygen delivery and reduces postbypass inflammatory mediator expression. Circulation (2003) 1.42
Invasive Mechanical Ventilation and Mortality in Pediatric Hematopoietic Stem Cell Transplantation: A Multicenter Study. Pediatr Crit Care Med (2016) 1.39
Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care (2012) 1.31
Contribution of MKP-1 regulation of p38 to endotoxin tolerance. Shock (2005) 1.28
Inpatient health care utilization for children dependent on long-term mechanical ventilation. Pediatrics (2011) 1.26
Effect of IL-10 on neutrophil recruitment and survival after Pseudomonas aeruginosa challenge. Am J Respir Cell Mol Biol (2008) 1.23
Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics (2010) 1.22
Corticosteroids are associated with repression of adaptive immunity gene programs in pediatric septic shock. Am J Respir Crit Care Med (2014) 1.20
Validation of the KDIGO acute kidney injury criteria in a pediatric critical care population. Intensive Care Med (2014) 1.18
Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. Crit Care (2011) 1.16
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Combining Prognostic and Predictive Enrichment Strategies to Identify Children With Septic Shock Responsive to Corticosteroids. Crit Care Med (2016) 1.08
Tracking the impact of the National Institutes of Health Clinical and Translational Science Awards on child health research: developing and evaluating a measurement strategy. Pediatr Res (2012) 1.08
The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol (2002) 1.07
An integrated microfluidic platform for in situ cellular cytokine secretion immunophenotyping. Lab Chip (2012) 1.06
Rapid fluid resuscitation in pediatrics: testing the American College of Critical Care Medicine guideline. Ann Emerg Med (2007) 1.02
Clinical implications and molecular mechanisms of immunoparalysis after cardiopulmonary bypass. J Thorac Cardiovasc Surg (2011) 1.00
Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics (2007) 1.00
Janus kinase 3 down-regulates lipopolysaccharide-induced IL-1 beta-converting enzyme activation by autocrine IL-10. J Immunol (2004) 0.99
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.99
Critical care for pediatric asthma: wide care variability and challenges for study. Pediatr Crit Care Med (2012) 0.99
Mitogen-activated protein kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect Immun (2010) 0.98
Ceramide-dependent PP2A regulation of TNFalpha-induced IL-8 production in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol (2009) 0.97
Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J (2011) 0.97
Immunoregulatory effects of regulated, lung-targeted expression of IL-10 in vivo. Am J Physiol Lung Cell Mol Physiol (2004) 0.96
Incidence and Outcomes of Cardiopulmonary Resuscitation in PICUs. Crit Care Med (2016) 0.96
Heat shock inhibits tnf-induced ICAM-1 expression in human endothelial cells via I kappa kinase inhibition. Shock (2002) 0.95
Effect of interhospital transfer on resource utilization and outcomes at a tertiary pediatric intensive care unit. J Crit Care (2009) 0.93
Pediatric Sepsis Biomarker Risk Model-II: Redefining the Pediatric Sepsis Biomarker Risk Model With Septic Shock Phenotype. Crit Care Med (2016) 0.93
Heat shock-mediated regulation of MKP-1. Am J Physiol Cell Physiol (2005) 0.92
Integrated nanoplasmonic sensing for cellular functional immunoanalysis using human blood. ACS Nano (2014) 0.91
Serotonin syndrome following a single 50 mg dose of sertraline in a child. Clin Toxicol (Phila) (2008) 0.89
PP2A regulates upstream members of the c-jun N-terminal kinase mitogen-activated protein kinase signaling pathway. Shock (2008) 0.89
Can peripheral blood mononuclear cells be used as a proxy for mitochondrial dysfunction in vital organs during hemorrhagic shock and resuscitation? Shock (2013) 0.89
Understanding the role of von Willebrand factor and its cleaving protease ADAM TS13 in the pathophysiology of critical illness. Pediatr Crit Care Med (2007) 0.87
Innate immune function predicts the development of nosocomial infection in critically injured children. Shock (2014) 0.86
Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost (2010) 0.86
Public participation in, and awareness about, medical research opportunities in the era of clinical and translational research. Clin Transl Sci (2013) 0.85